Top 5 Gas Utility Stocks To Invest In 2014

Source: Jon S., Flickr.

For decades, the publishing business formed the core of the media world, providing millions of people with their primary sources of entertainment and information through books and newspapers. The advent of television created some competition for the industry, but it wasn't until the rise of the Internet that traditional publishers experienced more substantial declines. With the ease of dissemination of content through online channels, traditional publishing has had to seek a way to keep itself from becoming obsolete. Let's take a closer look at the publishing industry to see whether it still offers any promising investment opportunities.

What is the publishing industry?

The publishing industry includes three primary segments. The highest-profile companies in publishing focus on newspapers, with The�New York Times, News Corp. and its Wall Street Journal, and the now privately held Washington Post gaining international recognition for their respective publications.

Best Stocks For 2015: National Instruments Corporation(NATI)

National Instruments Corporation designs, manufactures, and sells measurement and automation products to create virtual instrumentation systems for general, commercial, industrial, and scientific applications worldwide. The company sells or licenses application software and modular hardware that combines with industry-standard computers, networks, and third party devices to create measurement, automation, and embedded systems. Its system design software products include LabVIEW to design custom virtual instruments for scientists and engineers and provide data analysis, visualization, and sharing features; LabVIEW Real-Time and LabVIEW FPGA, which are modular software add-ons enabling users to configure their application programs and to build custom hardware devices for measurement or control protocols. The company also offers LabWindows/CVI programming environment for creating test and control applications; and Measurement Studio, which consists of measurement and automati on add-on libraries and additional tools for programmers. Its application software products include NI TestStand, a test management environment; NI VeriStand, a ready-to-use software environment; NI DIAdem that offers configuration-based technical data management, analysis, and report generation tools; and NI Multisim, which offers circuit design technology. In addition, the company provides hardware products and related driver software comprising data acquisition hardware/driver software, PXI modular instrumentation platform, modular instruments, machine vision/image acquisition, motion control, NI RIO hardware platform, industrial communications interfaces, GPIB interfaces/driver software, and VXI controllers/driver software. Further, it offers system configuration and deployment, calibration, warranty and repair, and customer training services, as well as software maintenance and technical support. National Instruments Corporation was founded in 1976 and is headquartered in Austin, Texas.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of scientific tools manufacturer National Instruments (NASDAQ: NATI  ) sank 13% today after its quarterly results and guidance missed Wall Street expectations. �

• [By Eric Volkman]

  National Instruments (NASDAQ: NATI  ) has elected to maintain its dividend. The company declared a distribution of $0.14 per share, to be paid on Sept. 3 to shareholders of record as of Aug. 12. That amount matches each of the company's previous six distributions, the most recent of which was paid at the beginning of June. Before that, National Instruments handed out $0.10 per share.

Top 5 Gas Utility Stocks To Invest In 2014: Teradyne Inc.(TER)

Teradyne, Inc., together with its subsidiaries, provides automatic test equipment products and services worldwide. The company operates in three segments: Semiconductor Test, Systems Test Group, and Wireless Test. The Semiconductor Test segment designs, manufactures, and sells semiconductor test products and services. Its test systems are used for wafer level and device package testing. These chips are used in automotive, communications, consumer, computer, and electronic game applications. This segment provides its products to integrated device manufacturers (IDMs) that integrate the fabrication of silicon wafers into their business; fabless companies, which outsource the manufacturing of silicon wafers; foundries that cater to the processing and manufacturing of silicon wafers; and outsourced sub-assembly and test providers, which offer test and assembly services for the final packaged devices to fabless companies and IDMs. It also provides Magnum test platform that test s memory devices, such as flash memory and dynamic random access memory, as well as offers ETS platform for use by semiconductor manufacturers, and assembly and test subcontractors in the low pin count analog/mixed signal discrete markets. The Systems Test Group segment offers military/aerospace test instrumentation and systems; storage test systems for HDD manufacturers; and circuit-board test and inspection systems for electronics manufacturers of cell phones, servers, computers, Internet switches, automobiles, and military avionics systems. The Wireless Test segment designs, develops, and supports wireless test solutions for developing and manufacturing wireless devices, such as smart phones, tablets, notebooks/laptops, and personal computer peripherals. This segment offers cellular communication solution for verification and calibration of mobile devices; and products for connectivity testing. The company was founded in 1960 and is headquartered in North Reading, Massach usetts.

Advisors' Opinion:

• [By James O'Toole]

  Facebook will replace testing equipment company Teradyne Inc. (TER)in the S&P 500 and energy infrastructure firm The Williams Companies (WMB, Fortune 500) in the S&P 100.

• [By Johnson Research Group]

  In addition, Perrigo has some potential support building below as the 20-day moving average is sneaking up to the $155 level. The potential for support from the technicals and a break above $160 will likely be enough to get the shorts to scramble and turn into buyers to cover their positions, helping a new rally in PRGO stock.

  Short Squeeze Candidate #3: Teradyne (TER)

  
  Click to Enlarge Technology shares have been seeing some shorts lately as traders are betting on a fade in the trend of technology leadership. Among the names on our short list for squeezes is Teradyne (TER).

• [By Dan Caplinger]

  Facebook certainly took the spotlight in the decision from S&P Dow Jones Indices to include the social media giant in the S&P 500. But lost in the Facebook news was the fact that Alliance Data Systems (NYSE: ADS  ) and Mohawk Industries (NYSE: MHK  ) also gained admission to the prestigious index, while Abercrombie & Fitch (NYSE: ANF  ) , JDS Uniphase (NASDAQ: JDSU  ) , and Teradyne (NYSE: TER  ) made their exit. Let's take a closer look at the other winners and losers in the Facebook index shuffle.

Top 5 Gas Utility Stocks To Invest In 2014: Onconova Therapeutics Inc (ONTX)

Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.

Rigosertib

Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.

ON 013105

The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.

Recilisib

The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.

Preclinical Programs

The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.

The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.

Advisors' Opinion:

• [By Roberto Pedone]

   

  One under-$10 clinical-state biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Onconova Therapeutics (ONTX), which focuses on discovering and developing small molecule drug candidates to treat cancer. This stock has been destroyed by the short-sellers so far in 2014, with shares off sharply by 56%.

   

  If you glance at the chart for Onconova Therapeutics, you'll notice that this stock has been trending sideways and consolidating right below its 50-day moving average for the last few weeks. This consolidation pattern is occurring right after shares of ONTX recently spiked sharply higher from its low of $4.10 to its high of $5.52 a share. Shares of ONTX are now trending within range of breaking out of that consolidation pattern and potentially heading higher.

   

  Traders should now look for long-biased trades in ONTX if it manages to break out above its 50-day moving average of $5.09 a share and then once it takes out some more key overhead resistance levels at $5.24 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 203,756 shares. If that breakout triggers soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $6.27 to $7 a share.

   

  Traders can look to buy ONTX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.75 to right around $4.50 a share. One can also buy ONTX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

   

Top 5 Gas Utility Stocks To Invest In 2014: LMP Real Estate Income Fund Inc (RIT)

LMP Real Estate Income Fund Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund�� primary investment objective is to provide high current income. Its secondary investment objective is capital appreciation. Legg Mason Partners Fund Advisor, LLC (LMPFA) is the Fund�� investment manager and AEW Management and Advisors, L.P. (AEW) is the Fund�� subadviser. LMPFA is a wholly owned subsidiary of Legg Mason, Inc.

The Fund invests in securities related to the real estate industry. Its portfolio includes common stocks, preferred stocks and short-term investments. The Fund invests in sectors, such as office, healthcare, diversified, apartments, industrial, shopping centers, home financing, lodging/resorts, regional malls and specialty.

Advisors' Opinion:

• [By Joe Eqcome]

  Actionable Items:

  Highest Positive Spread: Nuveen Mortgage Opportunity Term Fund (JLS)Focus Stock: LMP Real Estate Income Fund (RIT)Last Week's Focus Stock: ASA Gold and Precious Metals (ASA)

  ECB cuts its rates: The European Central Bank (ECB) will cut its benchmark rate a quarter-of-a-point to 0.5%.

• [By GURUFOCUS]

  Special Purpose Funds- Eaton Vance Tax-Adv. Global Dividend Oppor. Fund (ETO) | Yield: 7.3%
  - The Gabelli Global Utility & Income Trust (GLU) | Yield: 6.2%
  - Pimco Global Stocksplus Income Fund (PGP) | Yield: 9.5%
  - LMP Real Estate Income Fund Inc. (RIT) | Yield: 7.0%